INTRODUCTION
Splenic abnormalities are usually investigated by a combination of haematological and radiological assessment. Excluding trauma and vascular conditions, abnormalities manifest as splenomegaly or focal lesions on radiological investigations. Splenic biopsy is reserved for those with unexplained abnormality or considered in the presence of a known underlying malignancy, usually lymphoma, where histology is required for staging. 1 In such cases, biopsy of the spleen is considered when there is no other safer accessible site to obtain tissue for histology. 2 A commonly held view amongst clinicians is that there is significant morbidity associated with splenic biopsy. The major complication of concern is haemorrhage, but other complications include pneumothorax, pleural effusion and colonic injury. 3, 4 The perceived high rates of morbidity relate to an early study by Lindgren et al 5 using a 14-G core needle. There was a 13% major complication rate which was secondary to haemorrhage requiring transfusion and, in one case, haemorrhage requiring splenectomy. Since then, splenic lesions have been sampled by fine-needle aspiration (FNA) or core needle biopsy (CNB) with smaller needles. Most studies have used a 20-to 22-G FNA or CNB. The use of 18-G biopsy needles is relatively underreported, with a small number of cases within several studies. 6, 7 We present, to our knowledge, the largest series of ultrasound-guided splenic biopsy with an 18-G CNB assessing diagnostic and major complication rates.
METHODS AND MATERIALS
Consecutive referrals for ultrasound-guided splenic CNB performed from May 1990 to May 2015 to the Oncology Radiology Department at Southampton General Hospital were identified from the radiology information system. Case notes and discharge summaries were retrospectively reviewed in all cases for post-procedural complications. Histological diagnosis was obtained from laboratory reports. The following parameters were recorded onto a Microsoft ® Excel ® database (Microsoft, Redmond, WA): purpose of biopsy, number of previous biopsies, including site, presence of splenomegaly or focal splenic lesion, biopsy success and complications. A positive biopsy was one that demonstrated malignancy or was suspicious in keeping in line with the methodology by Tam et al. 8 Complications are stratified into minor and major complications as outlined by the reporting of interventional procedure guidelines by Omary et al. 9 All procedures were performed by a single consultant radiologist under ultrasound guidance, with the exception of one procedure that was performed by a radiology trainee under the supervision of the same consultant radiologist. An 18-G side-cutting CNB was used in all cases. This was used as a compromise between safety and diagnostic yield. Literature suggests a higher risk with larger bore biopsies (Lindgren et al 5 ) and lower yield with fine bore needles. The number of throws passed into the spleen was difficult to identify from older case notes and was not included in the study, but more recent biopsies have been limited to one or a maximum of two passes. During the study period, a range of ultrasound scanners were used, generally using a curvilinear probe (up to 5.0 MHz).
Pre-procedural assessment included checking clotting profile and full blood count and taking vital signs at admission or during their prior inpatient stay. Written informed consent from the patients was obtained. Ultrasound was performed to identify optimal patient positioning, usually in the right lateral decubitus position. A subcostal or intercostal sonographic window was identified and breath-holding instructions were practised with the patient. The procedure is performed under local anaesthetic with 1% lignocaine only down to the splenic capsule. The biopsy needle is placed under ultrasound guidance down to the splenic capsule. The patient then performs the instructed breath-hold technique, to bring the lesion into the field of view and the biopsy trajectory. The needle is advanced into the lesion, core biopsy was taken and the needle immediately withdrawn before breathing resumed (Figure 1 ). The aim of this technique is to reduce laceration to the splenic capsule.
RESULTS
A total of 52 splenic biopsies were performed in 47 patients during the study duration. Four patients had a repeat biopsy, with one of these patients having an additional repeat biopsy after two previous biopsies. Excluding these five cases of repeat splenic biopsy where the histology was inconclusive but suspicious, necessitating repeat biopsy, there was a positive diagnostic yield in 42 of 47 patients (89.4%). If repeat biopsies are included, the overall diagnostic yield is 90.4% (47/52 biopsies). The reason for failure in the other cases includes insufficient sample, necrotic or normal splenic tissue, in patients later diagnosed with diffuse large B-cell lymphoma at splenectomy.
The purpose of the biopsy was for establishing diagnosis in 44 cases (84.6%), restaging of malignancy in 2 cases (3.8%), identifying transformation of lymphoma in 3 cases (5.8%) and identifying relapse of disease in 1 case (1.9%). In two patients, the complete patient notes were not available for assessment. Patients were referred primarily for focal splenic lesions or with splenomegaly in patients with known haematological malignancy. Diffuse splenic disease from other causes such as infections, haemolysis, or metabolic or hepatic disease was not suspected in these patients prior to biopsy.
A previous biopsy from any site was performed in 23 cases (44.2%) which included the 5 prior splenic biopsies in 4 patients. The reason for rebiopsy was insufficient or necrotic samples but there remained a high degree of suspicion for malignancy. 14 patients had a prior bone marrow trephine biopsy which was inconclusive. One of these patients also underwent a mesenteric biopsy which was unsuccessful. Two patients had a previous lymph node biopsy, and one patient had a liver biopsy. In the others, the spleen was the only site of abnormality, or there was no safe alternative site.
Lymphoma was diagnosed in 29 of the 42 positive biopsies (69.0%), with 4 cases of adenocarcinoma (9.5%). Benign conditions were present in eight cases (19.0%). Table 1 summarizes the histological diagnosis seen in the positive biopsies.
Only 1 of the 52 biopsies (1.9%) demonstrated a significant postbiopsy complication. This patient had a post-biopsy subcapsular haematoma. The patient was readmitted post-procedure after initial discharge with abdominal pain and tachycardia. This was managed conservatively with no blood transfusion or the required therapeutic procedure.
DISCUSSION
Isolated splenic abnormalities are uncommon and may present as solitary or multiple splenic lesions or splenomegaly. Diagnosis may be made with correlation to patient's clinical history, laboratory findings or other radiological examinations, but where diagnosis remains unclear, tissue diagnosis is required. 10 There is a wide spectrum of diseases that affect the spleen, but often the primary aim of diagnosis is to exclude malignancy. In our case series of 42 diagnostic biopsies, there were 33 cases of malignancy (78.6%), which included 29 cases of lymphoma and 4 cases of metastatic adenocarcinoma (lung, adrenal and colon). The higher prevalence of malignancy in this series reflects a selection bias owing to splenic biopsy reserved in cases with diagnostic uncertainty or the need for more accurate histology in patients with known lymphoma for chemotherapy regimens.
Primary splenic lymphoma is rare, accounting for 1% of nonHodgkin's lymphoma in splenectomy cases. 11 It is difficult to completely determine whether disease is limited to the spleen; however, the spleen may be the only site of disease on imaging and therefore the only site amenable to biopsy. Splenectomy carries significant mortality (2.9%) and morbidity (37%), with infection being the most significant complication. 12, 13 Imageguided percutaneous biopsy of the spleen is now a recognised alternative to splenectomy.
The diagnostic yield of our case series was 89.4% for all patients with the reason for diagnostic failure being inadequate sample or necrotic tissue. If we include all positive biopsies, the diagnostic yield increases to 90.4% (47/52 biopsies). This includes the cases where the initial biopsy was highly suspicious for malignancy, but further tissue was required for full histological analysis. In the negative cases, the eventual diagnosis was idiopathic pulmonary haemosiderosis, splenic abscess, normal spleen in patients with previous lymphoma in two cases and a diagnosis of diffuse large B-cell lymphoma after splenectomy.
Previous studies 4, 14, 15 have varying diagnostic yields depending on the type of biopsy and size of needle. For FNA with a 20-to 22-G needle, the yield ranges from 62.8% to 88.9%. Although diagnostic yields are high with FNA, cytological analysis remains suboptimal compared with histological diagnosis due to loss of architectural analysis. This can wrongly classify the lymphoma subtype, with certain subtypes impossible to diagnose on cytological examination. 16 The diagnostic yield of ultrasound-guided 20-to 22-G CNB is 75-100%. 4, [17] [18] [19] Suzuki et al 18 and Cavanna et al 17 demonstrated a diagnostic yield of 97.8% and 100%, respectively. The higher positivity rate could be secondary to the lower case numbers in the study by Cavanna et al (n 5 8). Additionally, in both studies, the majority of patients had known lymphoma, and the biopsy was performed as part of a staging procedure which may lead to a higher rate of diagnostic accuracy. 17, 18 The use of 18-G CNB is underreported. Muraca et al 7 performed ultrasound-guided CNB in 30 children with an overall diagnostic yield of 83%; however, this is 100% for 18-G needles (n 5 15) and 75% for 20-to 21-G needles (n 5 20). López et al 20 also showed a 100% diagnostic yield with 18-G CNB in 13 cases. Liang et al 6 compared 18-G CNB against 21-G FNA with CNB and found a significantly higher yield with the 18-G biopsy with less number of passes and no additional complications. The overall diagnostic sensitivity in a metaanalysis by McInnes et al 21 is 87%, which includes 18-to 22-G biopsies. Table 2 summarizes the prior studies in the literature on ultrasound-guided percutaneous splenic biopsies, including diagnostic yield and complication rate. Pooled data for 20-to 25-G FNA, 20-to 22-G CNB and 18-to 19.5-G CNB demonstrate a diagnostic yield of 83.8%, 87.8% and 96.1%. These demonstrate a superior diagnostic yield for the 18-to 19.5-G CNB which is comparable to our study with a yield of 90.4%.
An alternative to percutaneous biopsy and splenectomy is laparoscopic splenic biopsy. However, this requires a general anaesthetic, is more invasive with difficult access to the spleen and is limited to visible surface lesions. Diagnosis, however, was only achieved in 70% of 57 patients in the study by Werner et al. 22 The major benefit is the control of haemorrhage at the time of biopsy with no post-procedural haemorrhage noted.
In our case series, there was one case of subcapsular haematoma which required overnight admission and conservative management. This is classified as a minor complication as outlined by Omary et al. 9 Major complications are those that require therapy, have permanent sequelae or lead to death. With splenic biopsy, this implies an intrasplenic or intra-abdominal haemorrhage requiring transfusion, embolization or splenectomy or a pneumothorax requiring chest drain insertion. Our major complication rate is 0% and minor complication rate is 2%, although we have not included pain as part of our postprocedural complications. Complication rates from previous studies are 0-2.9% for 20-to 25-G FNA, 4, 8, 14, 15, 19, 23 0-2.4% for ultrasound-guided 18-to 21-G CNB, 6, 7, 17, 18, 20 7.7% for CTguided CNB 2 and 12.5% for 14-G CNB. 5 It is difficult to correctly identify the minor complication rate as post-biopsy follow-up protocol differs amongst the previous studies, with some including imaging follow-up in all patients and others on a symptomatic basis. In our practice, imaging follow-up was not routinely performed post-biopsy and was only indicated if there was clinical concern. The major complication rate for the pooled biopsy data from Table 2 is more reflective of the safety of the procedure. Pooled major complication rates were 0.3% for 20-to 25-G FNA, 0.8% for 20-to 22-G CNB, 2.6% for 18-to 19.5-G CNB and 12.1% for 14-G CNB. This is compared to our major complication rate of 0%. The higher complication rates for 14-G biopsy is attributed to larger cores with haemorrhage occurring in four cases, three requiring transfusion and one splenectomy. The higher complication rate with CT-guided biopsy may be due to differing technique and probable laceration of the splenic capsule owing to breathing, with three cases of major haemorrhage requiring transfusion or embolization. 2 Post-procedural haemorrhage was the main complication reported, with only one case of pneumothorax, which was in a case series of 398 FNA by Civardi et al. 4 Mueller et al 24 demonstrated a 2.7% complication rate in 148 patients with focal liver lesions undergoing ultrasoundguided CNB with a 1.2-mm-diameter needle, which is comparable to 18-G needles. These complications were all minor complications and related to haemorrhage requiring conservative therapy. In 2 small series of 44 and 59 patients undergoing ultrasound-guided renal mass core biopsies, the complication rate was 9.1% and 20.7%, respectively. 25, 26 The higher complication rate was attributed to haematuria being a common minor complication after renal biopsy. No major complications were reported. Our complication is comparable to those of other abdominal organs commonly undergoing percutaneous biopsy with no noticeable significant major complications.
The limitations of our study are reflected by the relatively small number of consecutive but otherwise unselected cases despite being the largest series to date. Also, this was a retrospective study, and data such as the number of passes made into the spleen was difficult to ascertain from older cases over the 25-year period. Another limitation is that this was predominantly a single operator performing the biopsies.
CONCLUSION
Ultrasound-guided splenic biopsy with an 18-G core biopsy needle is a safe and accurate procedure with no evidence of increased risk of complications compared with smaller needles or biopsy of other abdominal organs.
